Philip Lipari

Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti–IGF-IR antibody

Yan Wang, Judith Hailey, Denise Williams et al. · Molecular Cancer Therapeutics · 2005 · 168 citations · Full text

Tumor Cell Growth, Human Growth, Immunology +16

Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer

Maya Gurnani, Philip Lipari, Janet Dell et al. · Cancer Chemotherapy and Pharmacology · 1999 · 109 citations

Greater Efficacy, Medicine, Pathology +9

Structure−Activity Relationship of 3-Substituted <i>N</i>-(Pyridinylacetyl)-4- (8-chloro-5,6-dihydro-11<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridin-11-ylidene)- piperidine Inhibitors of Farnesyl-Protein Transferase:  Design and Synthesis of in Vivo Active Antitumor Compounds

F. George Njoroge, Bancha Vibulbhan, Dinananth F. Rane et al. · Journal of Medicinal Chemistry · 1997 · 52 citations · Full text

Analogue 38, Analogues 19, Pharmacotherapy +16

Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction

Rumin Zhang, Todd Mayhood, Philip Lipari et al. · Analytical Biochemistry · 2004 · 49 citations · Full text

Molecular Biology, Anti-cancer Agent, Chemical Probe +2

A Fully Human Insulin-Like Growth Factor-I Receptor Antibody SCH 717454 (Robatumumab) Has Antitumor Activity as a Single Agent and in Combination with Cytotoxics in Pediatric Tumor Xenografts

Yaolin Wang, Philip Lipari, Xiaoying Wang et al. · Molecular Cancer Therapeutics · 2010 · 43 citations · Full text